MSB 3.21% $1.13 mesoblast limited

Great Company, Great Future!, page-49

  1. 90 Posts.
    lightbulb Created with Sketch. 20
    Got out o'here a while ago. Realised the tech was tricky and not fully understood with real manufacture, storage and administration issues for to be bigger than niche. Shotgun approach to clinical applications just indicates a whole bunch of fishing expeditions. Then big pharma balls-up and now a class action plus unimpressive FDA interactions Where's the good news?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.